EKSO BIONICS HOLDING (OTCBB:EKSO) reported that their participation in popular Rehab Week 2015 kicked off with an inaugural ECSO meeting. During this time, the group highlighted the groundwork needed for the clinical evidence seen essential as part of Standard of Care treatment. The company said that “The Kessler Institute and Rehabilitation Institute” of Chicago presented early data on outcomes related with use of the company’s GT robotic exoskeleton at the INRS.
The meeting
Ekso Bionics reported that the meeting will be attended by known clinicians and scientists from reputed research institutes around the globe. The first meeting was completed on June 8, 2015 and the second meeting will be carried out in early 2016. There will an extended team during the next meet. EKSO Bionics is established to define research goals and initiate vital trials. The aim is to encourage adoption from rehabilitation centres and make GT robotic exoskeleton available to patients who can gain from it.
The week
Rehab Week was a group effort of three global conferences, ICRAN, INRS, and ICVR. The three groups promoted intensive and cross-disciplinary knowledge. The company exhibited its products at the two booths, with expert clinicians present at venue to answer questions and to give demos of the Ekso GT exoskeleton coupled with Smart Assist software.
The expertise
EKSO BIONICS HOLDING (OTCBB:EKSO) is known to develop, design and market wearable robots also known as exoskeletons. These exoskeletons can be used in a variety of applications in the industrial, military and medical industry. The company is moving ahead with its products as more than 125 Ekso GT suits are available to patients in close to hundred worldwide recognised rehabilitation centres. The wearable robots have enabled people living with a lower extremity weakness to take more than 21 million steps.
In last trading session, the stock price of EKSO declined 1.97%to close the trading session at $1.25.
